An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation

被引:16
作者
Choonara, YE
Pillay, V
Carmichael, T
Danckwerts, MP
机构
[1] Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, Gauteng, South Africa
[2] Fac Hlth Sci, Dept Ophthalmol, ZA-2193 Johannesburg, Gauteng, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
cytomegalovirus retinitis; doughnut-shaped minitablet (DSMT); extended release; polylactide-co-glycolide (PLGA); biodegradation; intraocular implantation;
D O I
10.1016/j.ijpharm.2005.10.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel doughnut-shaped minitablet (DSMT) was developed and evaluated as a biodegradable intraocular drug delivery system for rate-modulated delivery of antiviral bioactives. The DSMT device was manufactured using a special set of punches fitted with a central-rod in a Manesty tableting press. The DSMT device released the antiretrovirals foscarnet and ganciclovir at a first-order rate. The erosion kinetics was assessed by gravimetric analysis and scanning electron microscopy. The device gradually eroded when immersed in simulated vitreous humor (SVH) (pH 7.4, 37 degrees C) and released bioactives in a sustained manner. The novel geometric design and veracity of the DSMT device was retained even after 24 weeks of erosion. When considering the duration of the bioactive released from the DSMT device, it was found that by the careful selection of the type and concentration of polymer employed in formulating the DSMT device, it was possible to produce a device that could release drug for any period up to 12 months. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 21 条
[1]   INTRAVITREAL GANCICLOVIR PHARMACOKINETICS IN RABBITS AND MAN [J].
ASHTON, P ;
BROWN, JD ;
PEARSON, PA ;
BLANDFORD, DL ;
SMITH, TJ ;
ANAND, R ;
NIGHTINGALE, SD ;
SANBORN, GE .
JOURNAL OF OCULAR PHARMACOLOGY, 1992, 8 (04) :343-347
[2]  
COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
[3]   Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant [J].
Davis, JL ;
Tabandeh, H ;
Feuer, WJ ;
Kumbhat, S ;
Roth, DB ;
Chaudhry, NA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 127 (03) :283-287
[4]   HIGH-DOSE INTRAVITREAL FOSCARNET IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN AIDS [J].
DIAZLLOPIS, M ;
ESPANA, E ;
MUNOZ, G ;
NAVEA, A ;
CHIPONT, E ;
CANO, J ;
MENEZO, JL ;
ROMERO, FJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (02) :120-124
[5]  
Hatton MP, 1998, RETINA-J RET VIT DIS, V18, P50, DOI 10.1097/00006982-199801000-00009
[6]   Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration.: Encapsulation technique, in vitro release profiles, and sterilization process [J].
Herrero-Vanrell, R ;
Ramirez, L ;
Fernandez-Carballido, A ;
Refojo, MF .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1323-1328
[7]  
Holbrook JT, 2003, ARCH OPHTHALMOL-CHIC, V121, P99
[8]   A CONTROLLED RETROSPECTIVE STUDY OF GANCICLOVIR TREATMENT FOR CYTOMEGALO-VIRUS RETINOPATHY - USE OF A STANDARDIZED SYSTEM FOR THE ASSESSMENT OF DISEASE OUTCOME [J].
HOLLAND, GN ;
BUHLES, WC ;
MASTRE, B ;
KAPLAN, HJ .
ARCHIVES OF OPHTHALMOLOGY, 1989, 107 (12) :1759-1766
[9]  
HOLLAND GN, 1987, OPHTHALMOLOGY, V94, P815
[10]   Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis [J].
Jabs, DA ;
Martin, BK ;
Forman, MS ;
Hubbard, L ;
Dunn, JP ;
Kempen, JH ;
Davis, JL ;
Weinberg, DV .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (01) :26-34